Inventor · disambiguated record
Allan R. Shepard
Also filed as: SHEPARD ALLAN · SHEPARD ALLAN R · SHEPARD ALLAN T
4 granted patents·31 pending applications·62 citations·filing 2003–2013
79Inventor score
Top patents by PatentIndex Score
35 records- 0193US7592324B2RNAi-mediated inhibition of ocular targetsALCON INC·Filed 2006·Granted Sep 22, 2009·26 cites·37 claims
- 0289US7838507B2RNAi inhibition of CTGF for treatment of ocular disordersALCON INC·Filed 2009·Granted Nov 23, 2010·13 cites·7 claims
- 0387US7622454B2RNAi inhibition of CTGF for treatment of ocular disordersALCON INC·Filed 2005·Granted Nov 24, 2009·10 cites·10 claims
- 0478US7351407B2Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON INC·Filed 2003·Granted Apr 1, 2008·13 cites·11 claims
- 0566US2007142376A1Control of intraocular pressure using alk5 modulation agentsALCON INC·Filed 2006·Application pending·0 cites
- 0664US2009326044A1RNAi-Mediated Inhibition of Ocular TargetsALCON RES LTD·Filed 2009·Application pending·0 cites
- 0764US2008057072A1Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disordersALCON MFG LTD·Filed 2007·Application pending·0 cites
- 0861US2009117098A1Complement C1Q Inhibitors For The Prevention And Treatment Of GlaucomaALCON RES LTD·Filed 2008·Application pending·0 cites
- 0959US2010120851A1Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucomaALCON RES LTD·Filed 2009·Application pending·0 cites
- 1058US2012115870A1Control of intraocular pressure using alk5 modulation agentsFLEENOR DEBRA L·Filed 2012·Application pending·0 cites
- 1157US2014094502A1RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERSNOVARTIS AG·Filed 2013·Application pending·0 cites
- 1257US2009202524A1Pai-1 expression and activity inhibitors for the treatment of ocular disordersALCON RES LTD·Filed 2009·Application pending·0 cites
- 1356US2008176964A1Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON RES LTD·Filed 2008·Application pending·0 cites
- 1454US2010166676A1RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONSALCON RES LTD·Filed 2010·Application pending·0 cites
- 1552US2007149616A1C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor HALCON MFG LTD·Filed 2006·Application pending·0 cites
- 1652US2011028534A1RNAi INHIBITION OF CTGF FOR TREATMENT OF OCULAR DISORDERSALCON INC·Filed 2010·Application pending·0 cites
- 1752US2007232675A1Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucomaALCON MFG LTD·Filed 2007·Application pending·0 cites
- 1852US2006134172A1Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON INC·Filed 2005·Application pending·0 cites
- 1951US2008025973A1Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disordersALCON MFG LTD·Filed 2007·Application pending·0 cites
- 2050US2010247548A1Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disordersALCON RES LTD·Filed 2010·Application pending·0 cites
- 2150US2011124708A1Rnai-mediated inhibition of ocular hypertension targetsALCON INC·Filed 2010·Application pending·0 cites
- 2247US2005239871A1Statins for the treatment of ocular hypertension and glaucomaALCON INC·Filed 2005·Application pending·0 cites
- 2347US2006020001A1Use of cathepsin k inhibitors for the treatment of glaucomaSHEPARD ALLAN·Filed 2003·Application pending·0 cites
- 2447US2009087413A1Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disordersALCON RES LTD·Filed 2008·Application pending·0 cites
- 2546US2006275797A1Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disordersALCON MFG LTD·Filed 2006·Application pending·0 cites
- 2646US2012101160A1Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteinsSHEPARD ALLAN·Filed 2005·Application pending·0 cites
- 2745US2011092523A1Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON RES LTD·Filed 2010·Application pending·0 cites
- 2845US2008153903A1Inhibitors of protein kinase c-delta for the treatment of glaucomaALCON MFG LTD·Filed 2007·Application pending·0 cites
- 2944US2012108632A1Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucomaSHEPARD ALLAN R·Filed 2012·Application pending·0 cites
- 3043US2005159432A1Short form c-Maf transcription factor antagonists for treatment of glaucomaALCON INC·Filed 2004·Application pending·0 cites
- 3143US2011105574A1Pai-1 expression and activity inhibitors for the treatment of ocular disordersALCON RES LTD·Filed 2011·Application pending·0 cites
- 3242US2011098314A1Statins for the treatment of ocular hypertension and glaucomaALCON INC·Filed 2010·Application pending·0 cites
- 3339US2010183629A1Antagonists of endothelial differentiation gene subfamily 3 (edg-3, s1p3) receptors for prevention and treatment of ocular disordersALCON RES LTD·Filed 2010·Application pending·0 cites
- 3431US2005005868A1Animal drinking water productionFiled 2004·Application pending·0 cites
- 3530US2010158897A1Pai-1 modulators for the treatment of ocular disordersALCON RES LTD·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Allan R. Shepard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →